Advertisement

DNA methylation episignature for Witteveen-Kolk syndrome due to SIN3A haploinsufficiency

Published:November 17, 2022DOI:https://doi.org/10.1016/j.gim.2022.10.004

      Abstract

      Purpose

      Witteveen-Kolk syndrome (WITKOS) is a rare, autosomal dominant neurodevelopmental disorder caused by heterozygous loss-of-function alterations in the SIN3A gene. WITKOS has variable expressivity that commonly overlaps with other neurodevelopmental disorders. In this study, we characterized a distinct DNA methylation epigenetic signature (episignature) distinguishing WITKOS from unaffected individuals as well as individuals with other neurodevelopmental disorders with episignatures and described 9 previously unpublished individuals with SIN3A haploinsufficiency.

      Methods

      We studied the phenotypic characteristics and the genome-wide DNA methylation in the peripheral blood samples of 20 individuals with heterozygous alterations in SIN3A. A total of 14 samples were used for the identification of the episignature and building of a predictive diagnostic biomarker, whereas the diagnostic model was used to investigate the methylation pattern of the remaining 6 samples.

      Results

      A predominantly hypomethylated DNA methylation profile specific to WITKOS was identified, and the classifier model was able to diagnose a previously unresolved test case. The episignature was sensitive enough to detect individuals with varying degrees of phenotypic severity carrying SIN3A haploinsufficient variants.

      Conclusion

      We identified a novel, robust episignature in WITKOS due to SIN3A haploinsufficiency. This episignature has the potential to aid identification and diagnosis of individuals with WITKOS.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      ACMG Member Login

      Are you an ACMG Member? Sign in for online access.

      Subscribe:

      Subscribe to Genetics in Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Aref-Eshghi E.
        • Bend E.G.
        • Colaiacovo S.
        • et al.
        Diagnostic utility of genome-wide DNA methylation testing in genetically unsolved individuals with suspected hereditary conditions.
        Am J Hum Genet. 2019; 104: 685-700https://doi.org/10.1016/j.ajhg.2019.03.008
        • Aref-Eshghi E.
        • Kerkhof J.
        • Pedro V.P.
        • et al.
        Evaluation of DNA methylation episignatures for diagnosis and phenotype correlations in 42 Mendelian neurodevelopmental disorders.
        Am J Hum Genet. 2020; 106 (Published correction appears in Am J Hum Genet. 2021;108(6):1161-1163): 356-370https://doi.org/10.1016/j.ajhg.2020.01.019
        • Aref-Eshghi E.
        • Rodenhiser D.I.
        • Schenkel L.C.
        • et al.
        Genomic DNA methylation signatures enable concurrent diagnosis and clinical genetic variant classification in neurodevelopmental syndromes.
        Am J Hum Genet. 2018; 102: 156-174https://doi.org/10.1016/j.ajhg.2017.12.008
        • Sadikovic B.
        • Levy M.A.
        • Aref-Eshghi E.
        Functional annotation of genomic variation: DNA methylation episignatures in neurodevelopmental Mendelian disorders.
        Hum Mol Genet. 2020; 29: R27-R32https://doi.org/10.1093/hmg/ddaa144
        • Sadikovic B.
        • Levy M.A.
        • Kerkhof J.
        • et al.
        Clinical epigenomics: genome-wide DNA methylation analysis for the diagnosis of Mendelian disorders.
        Genet Med. 2021; 23 (Published correction appears in Genet Med. 2021;23(11):2228): 1065-1074https://doi.org/10.1038/s41436-020-01096-4
        • Levy M.A.
        • McConkey H.
        • Kerkhof J.
        • et al.
        Novel diagnostic DNA methylation episignatures expand and refine the epigenetic landscapes of Mendelian disorders.
        HGG Adv. 2021; 3100075https://doi.org/10.1016/j.xhgg.2021.100075
        • Witteveen J.S.
        • Willemsen M.H.
        • Dombroski T.C.D.
        • et al.
        Haploinsufficiency of MeCP2-interacting transcriptional co-repressor SIN3A causes mild intellectual disability by affecting the development of cortical integrity.
        Nat Genet. 2016; 48: 877-887https://doi.org/10.1038/ng.3619
        • Balasubramanian M.
        • Dingemans A.J.M.
        • Albaba S.
        • et al.
        Comprehensive study of 28 individuals with SIN3A-related disorder underscoring the associated mild cognitive and distinctive facial phenotype.
        Eur J Hum Genet. 2021; 29: 625-636https://doi.org/10.1038/s41431-020-00769-7
        • Grzenda A.
        • Lomberk G.
        • Zhang J.S.
        • Urrutia R.
        Sin3: master scaffold and transcriptional corepressor.
        Biochim Biophys Acta. 2009; 1789: 443-450https://doi.org/10.1016/j.bbagrm.2009.05.007
        • Silverstein R.A.
        • Ekwall K.
        Sin3: a flexible regulator of global gene expression and genome stability.
        Curr Genet. 2005; 47: 1-17https://doi.org/10.1007/s00294-004-0541-5
        • Narumi-Kishimoto Y.
        • Araki N.
        • Migita O.
        • et al.
        Novel SIN3A mutation identified in a Japanese patient with Witteveen-Kolk syndrome.
        Eur J Med Genet. 2019; 62103547https://doi.org/10.1016/j.ejmg.2018.09.014
        • van Dongen L.C.M.
        • Wingbermühle E.
        • Dingemans A.J.M.
        • et al.
        Behavior and cognitive functioning in Witteveen-Kolk syndrome.
        Am J Med Genet A. 2020; 182: 2384-2390https://doi.org/10.1002/ajmg.a.61775
        • Richards S.
        • Aziz N.
        • Bale S.
        • et al.
        Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.
        Genet Med. 2015; 17: 405-424https://doi.org/10.1038/gim.2015.30
        • Moran S.
        • Arribas C.
        • Esteller M.
        Validation of a DNA methylation microarray for 850,000 CpG sites of the human genome enriched in enhancer sequences.
        Epigenomics. 2016; 8: 389-399https://doi.org/10.2217/epi.15.114
        • Aryee M.J.
        • Jaffe A.E.
        • Corrada-Bravo H.
        • et al.
        Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays.
        Bioinformatics. 2014; 30: 1363-1369https://doi.org/10.1093/bioinformatics/btu049
        • Chen Y.A.
        • Lemire M.
        • Choufani S.
        • et al.
        Discovery of cross-reactive probes and polymorphic CpGs in the Illumina Infinium HumanMethylation450 microarray.
        Epigenetics. 2013; 8: 203-209https://doi.org/10.4161/epi.23470
        • Pidsley R.
        • Zotenko E.
        • Peters T.J.
        • et al.
        Critical evaluation of the Illumina MethylationEPIC BeadChip microarray for whole-genome DNA methylation profiling.
        Genome Biol. 2016; 17: 208https://doi.org/10.1186/s13059-016-1066-1
        • Ho D.E.
        • Imai K.
        • King G.
        • Stuart E.A.
        MatchIt: nonparametric preprocessing for parametric causal inference.
        J Stat Softw. 2011; 42: 1-28https://doi.org/10.18637/jss.v042.i08
        • Ritchie M.E.
        • Phipson B.
        • Wu D.
        • et al.
        limma powers differential expression analyses for RNA-sequencing and microarray studies.
        Nucleic Acids Res. 2015; 43: e47https://doi.org/10.1093/nar/gkv007
        • Peters T.J.
        • Buckley M.J.
        • Statham A.L.
        • et al.
        De novo identification of differentially methylated regions in the human genome.
        Epigenetics Chromatin. 2015; 8: 6https://doi.org/10.1186/1756-8935-8-6
        • van der Spek J.
        • den Hoed J.
        • Snijders Blok L.
        • et al.
        Inherited variants in CHD3 show variable expressivity in Snijders Blok-Campeau syndrome.
        Genet Med. 2022; 24: 1283-1296https://doi.org/10.1016/j.gim.2022.02.014
        • Bend E.G.
        • Aref-Eshghi E.
        • Everman D.B.
        • et al.
        Gene domain-specific DNA methylation episignatures highlight distinct molecular entities of ADNP syndrome.
        Clin Epigenetics. 2019; 11: 64https://doi.org/10.1186/s13148-019-0658-5
        • Chater-Diehl E.
        • Ejaz R.
        • Cytrynbaum C.
        • et al.
        New insights into DNA methylation signatures: SMARCA2 variants in Nicolaides-Baraitser syndrome.
        BMC Med Genomics. 2019; 12: 105https://doi.org/10.1186/s12920-019-0555-y
        • Mirza-Schreiber N.
        • Zech M.
        • Wilson R.
        • et al.
        Blood DNA methylation provides an accurate biomarker of KMT2B-related dystonia and predicts onset.
        Brain. 2022; 145: 644-654https://doi.org/10.1093/brain/awab360
        • Courraud J.
        • Chater-Diehl E.
        • Durand B.
        • et al.
        Integrative approach to interpret DYRK1A variants, leading to a frequent neurodevelopmental disorder.
        Genet Med. 2021; 23: 2150-2159https://doi.org/10.1038/s41436-021-01263-1